Cardiovascular Diseases

Intensive BP Control Benefits T2D Patients

A Chinese parallel design, randomized clinical trial showed that the incidence of major cardiovascular events among patients with type 2 diabetes (T2D) was significantly lower with intensive treatment targeting a systolic blood pressure (SBP) of less than 120 mm Hg than with standard treatment targeting a SBP of less than 140 mm Hg. A total of 12,821 T2D patients 50 years of age or older (mean age 63.8 years, 45.3% women; 6414 patients in the intensive-treatment group and 6407 in the standard-treatment group) were enrolled from February 2019 through December 2021. At 1 year of follow-up, the mean SBP was 121.6 (median, 118.3) mm Hg in the intensive-treatment group and 133.2 (median, 135.0) mm Hg in the standard-treatment group. During a median follow-up of 4.2 years, primary-outcome events (a composite of nonfatal stroke, nonfatal myocardial infarction, treatment or hospitalization for heart failure, or death from cardiovascular causes) occurred in 393 patients (1.65 events per 100 person-years) in the intensive-treatment group and 492 patients (2.09 events per 100 person-years) in the standard-treatment group (hazard ratio, 0.79). Fatal or nonfatal stroke, the most common type of cardiovascular disease among Chinese, occurred in 284 patients (1.19 events per 100 person-years) in the intensive-treatment group and in 356 patients (1.50 events per 100 person-years) in the standard-treatment group (hazard ratio, 0.79). The benefits of intensive BP control were consistent across all prespecified subgroups. The incidence of serious adverse events was similar in the groups. However, symptomatic hypotension and hyperkalemia occurred more frequently in the intensive-treatment group than in the standard-treatment group. The finding is consistent with some other trials and provides convincing evidence of the benefits of lowering SBP to a target of less than 120 mm Hg in T2D patients. The benefits of lowering SBP to a target of less than 120 mm Hg is known in patients without diabetes. Source: https://www.nejm.org/

hyangiu

Recent Posts

Lifestyle Intervention May Slow Early Cerebral Small-Vessel Injury

A secondary MRI analysis of the US POINTER randomized clinical trial found that a structured…

8 hours ago

Shared and Region-Specific Dementia Risk Factors

Dementia risk factors vary substantially across countries, but they frequently cluster together in similar patterns…

14 hours ago

Comparative Benefits and Risks of Anti-Obesity Drugs

A systematic review and network meta-analysis of 262 randomized trials involving 99,791 participants found that…

3 days ago

Early Mild Hypertrophic Cardiomyopathy May Still Carry Significant Cardiovascular Risk

Approximately 21% of patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events…

5 days ago

High-Intensity Interval Exercise Reduces Energy Intake in Adults With Overweight or Obesity

A Danish randomized crossover trial found that a single session of high-intensity interval exercise (HIIE)…

6 days ago

Proton Pump Inhibitor and Antibiotic Use May Reduce the Benefit of Immunotherapy in NSCLC

Baseline use of proton pump inhibitors (PPIs) and, to a lesser extent, antibiotics was associated…

1 week ago

This website uses cookies.